Document detail
ID
oai:pubmedcentral.nih.gov:1008...
Topic
ReviewAuthor
Marques, Cristiana Ferreira da Silva, Filipa Sousa, Isabel Nave, MónicaLangue
enEditor
BMJ Publishing Group
Category
BMJ Open Access
Year
2023
listing date
9/4/2023
Keywords
ovarian cancerAbstract
Advanced ovarian cancer remains a leading cause of death from gynecologic malignancy.
Surgery and, in most cases, platinum-based chemotherapy with or without maintenance with bevacizumab and/or poly-ADP ribose polymerase inhibitors (PARPi) represent the mainstay of treatment, but the disease typically recurs.
The treatment of these patients represents a clinical challenge because sequential chemotherapy regimens are often used, with suboptimal outcomes and cumulative toxicity.
Chemotherapy-free regimens, based on combinations of PARPi, vascular endothelial growth factor receptor inhibitors, anti-programmed cell death protein-1/programmed death-ligand 1, and anti-cytotoxic T-lymphocyte-associated protein-4 antibodies, among others, represent a valid option, with manageable toxicity profile and ease of administration.
This review addresses this new strategy in the management of recurrent ovarian cancer and discusses its feasibility in the treatment landscape of the disease.
Marques, Cristiana,Ferreira da Silva, Filipa,Sousa, Isabel,Nave, Mónica, 2023, Chemotherapy-free treatment of recurrent advanced ovarian cancer: myth or reality?, BMJ Publishing Group
Evaluating Image Hallucination in Text-to-Image Generation with Question-Answering
evaluation computer dataset images tti generation i-halla
Role of Repetitive Transcranial Magnetic Stimulation in Treatment of Fibromyalgia: A Randomized Controlled Trial
significant following stimulation fms treatment
